AgeX Therapeutics Inc (AGE)

Senolytic Drug Market Report | AgeX Therapeutics, Inc., Cleara Biotech - Motions Online

Motions Online

AgeX Therapeutics (NYSE:AGE) Trading Down 11.9% - Defense World

Defense World

Obesity Pipeline Insights Report 2024 (Updated) | 180 Life - openPR

openPR

Serina Therapeutics: Strategic Restructuring and Merger Success - TipRanks.com - TipRanks

TipRanks

Serina completes AgeX merger, targets neurological diseases and pain - Longevity.Technology

Longevity.Technology

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics - GlobeNewswire

GlobeNewswire

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

GlobeNewswire Inc.

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results - Yahoo Finance

Yahoo Finance

BioTime spinning out regenerative med firm AgeX - BioProcess Insider

BioProcess Insider

AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Business Wire

Business Wire

AgeX Therapeutics Postpones Merger Completion with Serina - TipRanks.com - TipRanks

TipRanks

Why IBM Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket

Benzinga

2023's biotech reverse mergers - BioCentury

BioCentury

Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer - GlobeNewswire

GlobeNewswire

AgeX Therapeutics Reports Third Quarter 2023 Financial Results - Business Wire

Business Wire

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - CNSL, SPLK, AVTA, AGE - PR Newswire

PR Newswire

Serina-AgeX merger to develop SER-252 therapy for advanced... - Parkinson's News Today

Parkinson's News Today

Serina, AgeX Enter Merger Agreement - Contract Pharma

Contract Pharma

AgeX to merge with Serina Therapeutics - Longevity.Technology

Longevity.Technology

Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement - Business Wire

Business Wire

AgeX keeps defying time, coming through another quarter despite multiyear cash crunch - Fierce Biotech

Fierce Biotech

Publicly traded longevity companies announce new finance - Longevity.Technology

Longevity.Technology

AgeX Therapeutics Announces Appeal of NYSE American Determination - Yahoo Finance

Yahoo Finance

The Longevity biotech industry is hitting its stride - Longevity.Technology

Longevity.Technology

Time may be running out for anti-aging biotech AgeX as funds dry up - Fierce Biotech

Fierce Biotech

AgeX Therapeutics' Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001 - Business Wire

Business Wire

AgeX Therapeutics and LyGenesis Terminate Merger Negotiations - Business Wire

Business Wire

AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement - Business Wire

Business Wire

AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade ... - Business Wire

Business Wire

AgeX is developing rejuvenation biotechnology - Lifespan.io News

Lifespan.io News

AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to ... - Business Wire

Business Wire

AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for ... - Business Wire

Business Wire

AgeX Therapeutics: Revolutionary Potential But Extremely Early (NYSE:SER) - Seeking Alpha

Seeking Alpha

Michael West Discusses AgeX Therapeutics - Lifespan.io News

Lifespan.io News

The Top 10 Companies Working to Increase Longevity - Nanalyze

Nanalyze

AgeX Therapeutics Reports Publication of Data Supporting Type II Diabetes and Obesity Therapy - Equities News

Equities News

AgeX Therapeutics (AGE) Stock Price, News & Analysis - MarketBeat

MarketBeat

BioTime Makes Key Clinical Progress; SOTP Now $4.40/Share - Forbes

Forbes

AgeX Therapeutics | AgeX Therapeutics - AgeX Therapeutics

AgeX Therapeutics